ClinicalTrials.gg
CompletedNCT04809818Updated Mar 2, 2026Results posted

A Study to Evaluate Safety and PK of Multiple Doses of LT3001 Drug Product and Drug-drug Interaction in Healthy Subjects

A Phase 1 interventional study of LT3001 drug product and Placebo in Acute Ischemic Stroke, sponsored by Lumosa Therapeutics Co., Ltd.. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-02.

Sponsored by Lumosa Therapeutics Co., Ltd. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
65
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 480 studies in Ischemic Stroke with a site in United States — 122 open to participants now, 146 under way, 13 of them phase 3. Ischemic Stroke · United States.

Enrollment
183rd of 364
65 · median 66
Started
2021
with 36 others
Phase 1
37 of 480
4 open now
Registered
295th of 480
by date

Among the 480 studies in Ischemic Stroke with a site in United States, this one is the 183rd largest by enrollment of the 364 interventional ones that give a count, is one of 37 that started in 2021, is one of 37 in phase 1, and was the 295th registered.

Ischemic Stroke

2,619 studies on the registry are indexed under Ischemic Stroke; 978 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

122 of the 480 studies in Ischemic Stroke with a site in United States are open now. Recruiting first, the newest first:

117 more — sign in →

All 122 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 662 Ischemic Stroke studies recruiting now, 396 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 26 take children under 18; 42 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 480 studies in Ischemic Stroke with a site in United States, or all of them as a file.
02

Study summary

This Phase 1 study is planned to establish the clinical safety and pharmacokinetics profile of multiple dose of LT3001 drug product and to investigate drug interactions of LT3001 with potential concomitant medications in healthy subjects.

Read the detailed description

This study is a two-part study. Part A is double-blind, placebo-controlled, and will examine the safety and PK profiles of multiple doses of LT3001 drug product in healthy subjects. Part B is open-label and will assess the safety and PK of LT3001 when coadministered with aspirin, clopidogrel, apixaban or dabigatran.

03

Conditions studied

  • Acute Ischemic Stroke

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject's body weight is ≥50 kg and is within the range of 18 to 32
  • Subject is a healthy volunteer.
  • Subject's PT, , and TT are within the normal laboratory range.
  • Subject is a nonsmoker

Exclusion criteria

Exclusion Criteria:

  • Subject has a current or recent history of regular alcohol consumption.
  • Subjects who are enrolled in Part B and allergic to acetylsalicylic acid, other salicylates, clopidogrel, thienopyridines (eg, ticlopidine, prasugrel), apixaban or dabigatran.
  • Part B Cohort 2 only: subjects who are poor metabolizers of clopidogrel (CYP2C19*2/*2, *2/*3, or *3/*3 genotype)
  • Subject has a presence or history of coagulation abnormality.
  • Subjects need to receive a surgery or clinical procedures associated with high bleeding risk.
  • Subject has a history of minor bleeding episodes, eg, epistaxis, rectal bleeding, gingival bleeding.
  • Subject has a history of peptic ulcer or gastrointestinal bleeding.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
65 participants (actual)

Study arms

  • Experimental
    Part A - LT3001 Drug Product

    Multiple doses of LT3001 administered by intravenous infusion

    Drug: LT3001 drug product

  • Placebo comparator
    Part A - Placebo

    Multiple doses of Placebo administered by intravenous infusion

    Drug: Placebo

  • Experimental
    Part B - LT3001 and Aspirin

    Multiple doses of LT3001 and Aspirin administered

    Drug: LT3001 drug product · Drug: Aspirin

  • Experimental
    Part B - LT3001 and Clopidogrel

    Multiple doses of LT3001 and Clopidogrel administered

    Drug: LT3001 drug product · Drug: Clopidogrel

  • Experimental
    Part B - LT3001 and Apixaban

    Multiple doses of LT3001 and Apixaban administered

    Drug: LT3001 drug product · Drug: Apixaban

  • Experimental
    Part B - LT3001 and Dabigatran

    Multiple doses of LT3001 and Dabigatran administered

    Drug: LT3001 drug product · Drug: Dabigatran

Interventions

  • Multiple doses of LT3001 drug product administered by intravenous infusion

    Also known as: LT3001 injection

  • DrugPlacebo

    Multiple doses of Placebo administered by intravenous infusion

    Also known as: Placebo of LT3001 drug product

  • Loading and maintenance doses of Aspirin administered by oral

    Also known as: Aspirin tablet

  • Loading and maintenance doses of Clopidogrel administered by oral

    Also known as: Clopidogrel tablet

  • Multiple doses of Apixaban administered by oral

    Also known as: Eliquis®

  • Multiple doses of Dabigatran administered by oral

    Also known as: Pradaxa®

06

What researchers measure

Primary outcomes

  1. Number of Adverse Events

    To evaluate the safety and tolerability of LT3001 administered alone or in combination with aspirin, clopidogrel, apixaban, or dabigatran, as determined by the number and severity of adverse events collected from baseline through Day 4 post-baseline in Part A, and from baseline through Day 16 post-baseline in Part B.

    Time frame: Adverse events were assessed from baseline through Day 4 post-baseline in Part A, and from baseline through Day 16 post-baseline in Part B.

Secondary outcomes

  1. Change From Baseline in Activated Partial Thromboplastin Time (APTT)

    Change from baseline in activated partial thromboplastin time (APTT), measured in seconds, was assessed to evaluate the safety of LT3001 administered alone or in combination with aspirin, clopidogrel, apixaban, or dabigatran from baseline up to 16 days post-dose.

    Time frame: 16 days

  2. Number of Participants With Prolongation in Platelet Function Test

    The outcome measured the number of participants with prolongation in platelet function test results following administration of LT3001 alone or in combination with aspirin, clopidogrel, apixaban, or dabigatran. Platelet function was assessed using collagen/epinephrine and collagen/ADP assays. Results were evaluated from baseline up to 16 days post-dose. Participants in the Part A placebo group did not undergo platelet function testing and were therefore not included in this outcome analysis.

    Time frame: 16 days

  3. Plasma PK Parameters of LT3001 - Cmax

    Plasma concentrations of LT3001 and derived PK parameters up to 10 days after a single dose or multiple doses intravenous infusion of LT3001.

    Time frame: Predose and post-dose time points up to 10 days after dosing

  4. Plasma PK Parameters of LT3001 - Tmax

    Plasma concentrations of LT3001 and derived PK parameters up to 10 days after a single dose or multiple doses intravenous infusion of LT3001.

    Time frame: 10 days

  5. Plasma PK Parameters of LT3001 - AUC

    Plasma concentrations of LT3001 and derived PK parameters up to 10 days after a single dose or multiple doses intravenous infusion of LT3001.

    Time frame: 10 days

  6. Plasma PK Parameters of Aspirin - Cmax

    Plasma concentrations of Aspirin and derived PK parameters up to 8 days after multiple doses of Aspirin were administered.

    Time frame: 8 days

  7. Plasma PK Parameters of Aspirin - Tmax

    Plasma concentrations of Aspirin and derived PK parameters up to 8 days after multiple doses of Aspirin were administered.

    Time frame: 8 days

  8. Plasma PK Parameters of Aspirin - AUC

    Plasma concentrations of Aspirin and derived PK parameters up to 8 days after multiple doses of Aspirin were administered.

    Time frame: 8 days

  9. Plasma PK Parameters of Clopidogrel - Cmax

    Plasma concentrations of Clopidogrel and derived PK parameters up to 10 days after multiple doses of Clopidogrel were administered.

    Time frame: 10 days

  10. Plasma PK Parameters of Clopidogrel - Tmax

    Plasma concentrations of Clopidogrel and derived PK parameters up to 10 days after multiple doses of Clopidogrel administered (alone or with LT3001).

    Time frame: 10 days

  11. Plasma PK Parameters of Clopidogrel - AUC

    Plasma concentrations of Clopidogrel and derived PK parameters up to 10 days after multiple doses of Clopidogrel were administered.

    Time frame: 10 days

  12. Plasma PK Parameters of Apixaban - Cmax

    Plasma concentrations of Apixaban and derived PK parameters up to 8 days after multiple doses of Apixaban were administered.

    Time frame: 8 days

  13. Plasma PK Parameters of Apixaban - Tmax

    Plasma concentrations of Apixaban and derived PK parameters up to 8 days after multiple doses of Apixaban were administered.

    Time frame: 8 days

  14. Plasma PK Parameters of Apixaban - AUC

    Plasma concentrations of Apixaban and derived PK parameters up to 8 days after multiple doses of Apixaban were administered.

    Time frame: 8 days

  15. Plasma PK Parameters of Dabigatran - Cmax

    Plasma concentrations of Dabigatran and derived PK parameters up to 8 days after multiple doses of Dabigatran were administered.

    Time frame: 8 days

  16. Plasma PK Parameters of Dabigatran - Tmax

    Plasma concentrations of Dabigatran and derived PK parameters up to 8 days after multiple doses of Dabigatran administered (alone or with LT3001).

    Time frame: 8 days

  17. Plasma PK Parameters of Dabigatran - AUC

    Plasma concentrations of Dabigatran and derived PK parameters up to 8 days after multiple doses of Dabigatran administered (alone or with LT3001).

    Time frame: 8 days

07

Results

Posted Feb 6, 2026

Participant flow

Participant flow — Overall Study
MilestonePart A - LT3001 Drug ProductPart A - PlaceboPart B - LT3001 and AspirinPart B - LT3001 and ClopidogrelPart B - LT3001 and ApixabanPart B - LT3001 and Dabigatran
Started12413121212
Completed12412121212
Not completed001000

Outcome measures

PrimaryNumber of Adverse Events

To evaluate the safety and tolerability of LT3001 administered alone or in combination with aspirin, clopidogrel, apixaban, or dabigatran, as determined by the number and severity of adverse events collected from baseline through Day 4 post-baseline in Part A, and from baseline through Day 16 post-baseline in Part B.

Time frame:
Adverse events were assessed from baseline through Day 4 post-baseline in Part A, and from baseline through Day 16 post-baseline in Part B.
Reported as:
Number · event
Number of Adverse Events
eventPart A - LT3001 Drug ProductPart A - PlaceboPart B - LT3001 and AspirinPart B - LT3001 and ClopidogrelPart B - LT3001 and ApixabanPart B - LT3001 and Dabigatran
Number of Adverse Events302221
SecondaryChange From Baseline in Activated Partial Thromboplastin Time (APTT)

Change from baseline in activated partial thromboplastin time (APTT), measured in seconds, was assessed to evaluate the safety of LT3001 administered alone or in combination with aspirin, clopidogrel, apixaban, or dabigatran from baseline up to 16 days post-dose.

Time frame:
16 days
Reported as:
Mean · second
Change From Baseline in Activated Partial Thromboplastin Time (APTT)
secondPart A - LT3001 Drug ProductPart A - PlaceboPart B - LT3001 and AspirinPart B - LT3001 and ClopidogrelPart B - LT3001 and ApixabanPart B - LT3001 and Dabigatran
Change From Baseline in Activated Partial Thromboplastin Time (APTT)-0.62 ± 0.888-0.58 ± 0.8302.62 ± 5.5761.75 ± 3.3490.009 ± 1.4076.83 ± 4.003
SecondaryNumber of Participants With Prolongation in Platelet Function Test

The outcome measured the number of participants with prolongation in platelet function test results following administration of LT3001 alone or in combination with aspirin, clopidogrel, apixaban, or dabigatran. Platelet function was assessed using collagen/epinephrine and collagen/ADP assays. Results were evaluated from baseline up to 16 days post-dose. Participants in the Part A placebo group did not undergo platelet function testing and were therefore not included in this outcome analysis.

Time frame:
16 days
Reported as:
Count of participants · Participants
Number of Participants With Prolongation in Platelet Function Test
ParticipantsPart A - LT3001 Drug ProductPart B - LT3001 and AspirinPart B - LT3001 and ClopidogrelPart B - LT3001 and ApixabanPart B - LT3001 and Dabigatran
collagen/epinephrine01100
collagen/ADP15402
SecondaryPlasma PK Parameters of LT3001 - Cmax

Plasma concentrations of LT3001 and derived PK parameters up to 10 days after a single dose or multiple doses intravenous infusion of LT3001.

Time frame:
Predose and post-dose time points up to 10 days after dosing
Reported as:
Mean · ng/mL
Plasma PK Parameters of LT3001 - Cmax
ng/mLPart A - LT3001 Drug ProductPart B - LT3001 and AspirinPart B - LT3001 and ClopidogrelPart B - LT3001 and ApixabanPart B - LT3001 and Dabigatran
Plasma PK Parameters of LT3001 - Cmax48.86 ± 17.0645.30 ± 12.3143.23 ± 9.56942.28 ± 15.6243.96 ± 12.57
SecondaryPlasma PK Parameters of LT3001 - Tmax

Plasma concentrations of LT3001 and derived PK parameters up to 10 days after a single dose or multiple doses intravenous infusion of LT3001.

Time frame:
10 days
Reported as:
Mean · hour
Plasma PK Parameters of LT3001 - Tmax
hourPart A - LT3001 Drug ProductPart B - LT3001 and AspirinPart B - LT3001 and ClopidogrelPart B - LT3001 and ApixabanPart B - LT3001 and Dabigatran
Plasma PK Parameters of LT3001 - Tmax0.22 ± 0.0540.18 ± 0.0730.21 ± 0.0540.24 ± 0.0570.21 ± 0.043
SecondaryPlasma PK Parameters of LT3001 - AUC

Plasma concentrations of LT3001 and derived PK parameters up to 10 days after a single dose or multiple doses intravenous infusion of LT3001.

Time frame:
10 days
Reported as:
Mean · h*ng/mL
Plasma PK Parameters of LT3001 - AUC
h*ng/mLPart A - LT3001 Drug ProductPart B - LT3001 and AspirinPart B - LT3001 and ClopidogrelPart B - LT3001 and ApixabanPart B - LT3001 and Dabigatran
Plasma PK Parameters of LT3001 - AUC11.87 ± 3.3649.820 ± 3.00210.21 ± 2.07310.32 ± 3.1739.769 ± 2.558
SecondaryPlasma PK Parameters of Aspirin - Cmax

Plasma concentrations of Aspirin and derived PK parameters up to 8 days after multiple doses of Aspirin were administered.

Time frame:
8 days
Reported as:
Mean · ng/mL
Plasma PK Parameters of Aspirin - Cmax
ng/mLPart B - LT3001 and Aspirin
Plasma PK Parameters of Aspirin - Cmax477 ± 362.5
SecondaryPlasma PK Parameters of Aspirin - Tmax

Plasma concentrations of Aspirin and derived PK parameters up to 8 days after multiple doses of Aspirin were administered.

Time frame:
8 days
Reported as:
Mean · hour
Plasma PK Parameters of Aspirin - Tmax
hourPart B - LT3001 and Aspirin
Plasma PK Parameters of Aspirin - Tmax3.7 ± 2.3
SecondaryPlasma PK Parameters of Aspirin - AUC

Plasma concentrations of Aspirin and derived PK parameters up to 8 days after multiple doses of Aspirin were administered.

Time frame:
8 days
Reported as:
Mean · h*ng/mL
Plasma PK Parameters of Aspirin - AUC
h*ng/mLPart B - LT3001 and Aspirin
Plasma PK Parameters of Aspirin - AUC1709 ± 1251
SecondaryPlasma PK Parameters of Clopidogrel - Cmax

Plasma concentrations of Clopidogrel and derived PK parameters up to 10 days after multiple doses of Clopidogrel were administered.

Time frame:
10 days
Reported as:
Mean · ng/mL
Plasma PK Parameters of Clopidogrel - Cmax
ng/mLPart B - LT3001 and Clopidogrel
Plasma PK Parameters of Clopidogrel - Cmax3.925 ± 1.991
SecondaryPlasma PK Parameters of Clopidogrel - Tmax

Plasma concentrations of Clopidogrel and derived PK parameters up to 10 days after multiple doses of Clopidogrel administered (alone or with LT3001).

Time frame:
10 days
Reported as:
Mean · hour
Plasma PK Parameters of Clopidogrel - Tmax
hourPart B - LT3001 and Clopidogrel
Plasma PK Parameters of Clopidogrel - Tmax2.0 ± 1.0
SecondaryPlasma PK Parameters of Clopidogrel - AUC

Plasma concentrations of Clopidogrel and derived PK parameters up to 10 days after multiple doses of Clopidogrel were administered.

Time frame:
10 days
Reported as:
Mean · h*ng/mL
Plasma PK Parameters of Clopidogrel - AUC
h*ng/mLPart B - LT3001 and Clopidogrel
Plasma PK Parameters of Clopidogrel - AUC8.255 ± 5.129
SecondaryPlasma PK Parameters of Apixaban - Cmax

Plasma concentrations of Apixaban and derived PK parameters up to 8 days after multiple doses of Apixaban were administered.

Time frame:
8 days
Reported as:
Mean · ng/mL
Plasma PK Parameters of Apixaban - Cmax
ng/mLPart B - LT3001 and Apixaban
Plasma PK Parameters of Apixaban - Cmax188.5 ± 76.11
SecondaryPlasma PK Parameters of Apixaban - Tmax

Plasma concentrations of Apixaban and derived PK parameters up to 8 days after multiple doses of Apixaban were administered.

Time frame:
8 days
Reported as:
Mean · hour
Plasma PK Parameters of Apixaban - Tmax
hourPart B - LT3001 and Apixaban
Plasma PK Parameters of Apixaban - Tmax3.1 ± 1.5
SecondaryPlasma PK Parameters of Apixaban - AUC

Plasma concentrations of Apixaban and derived PK parameters up to 8 days after multiple doses of Apixaban were administered.

Time frame:
8 days
Reported as:
Mean · h*ng/mL
Plasma PK Parameters of Apixaban - AUC
h*ng/mLPart B - LT3001 and Apixaban
Plasma PK Parameters of Apixaban - AUC593.8 ± 26.7
SecondaryPlasma PK Parameters of Dabigatran - Cmax

Plasma concentrations of Dabigatran and derived PK parameters up to 8 days after multiple doses of Dabigatran were administered.

Time frame:
8 days
Reported as:
Mean · ng/mL
Plasma PK Parameters of Dabigatran - Cmax
ng/mLPart B - LT3001 and Dabigatran
Plasma PK Parameters of Dabigatran - Cmax146.1 ± 30.77
SecondaryPlasma PK Parameters of Dabigatran - Tmax

Plasma concentrations of Dabigatran and derived PK parameters up to 8 days after multiple doses of Dabigatran administered (alone or with LT3001).

Time frame:
8 days
Reported as:
Mean · hour
Plasma PK Parameters of Dabigatran - Tmax
hourPart B - LT3001 and Dabigatran
Plasma PK Parameters of Dabigatran - Tmax4.1 ± 1.2
SecondaryPlasma PK Parameters of Dabigatran - AUC

Plasma concentrations of Dabigatran and derived PK parameters up to 8 days after multiple doses of Dabigatran administered (alone or with LT3001).

Time frame:
8 days
Reported as:
Mean · h*ng/mL
Plasma PK Parameters of Dabigatran - AUC
h*ng/mLPart B - LT3001 and Dabigatran
Plasma PK Parameters of Dabigatran - AUC1807 ± 405.3

Adverse events

Collected over Adverse events were assessed from baseline through Day 4 post-baseline in Part A, and from baseline through Day 16 post-baseline in Part B.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part A - LT3001 Drug Product0/12 (0%)0/12 (0%)3/12 (25%)
Part A - Placebo0/4 (0%)0/4 (0%)0/4 (0%)
Part B - LT3001 and Aspirin0/12 (0%)0/12 (0%)2/12 (16.7%)
Part B - LT3001 and Clopidogrel0/12 (0%)0/12 (0%)2/12 (16.7%)
Part B - LT3001 and Apixaban0/12 (0%)0/12 (0%)2/12 (16.7%)
Part B - LT3001 and Dabigatran0/12 (0%)0/12 (0%)1/12 (8.3%)
Most frequent other events
Showing 10 of 11
Most frequent other events
EventPart A - LT3001 Drug ProductPart A - PlaceboPart B - LT3001 and AspirinPart B - LT3001 and ClopidogrelPart B - LT3001 and ApixabanPart B - LT3001 and Dabigatran
Abdominal painGastrointestinal disorders1/120/40/122/120/120/12
HeadacheNervous system disorders1/120/40/122/120/120/12
Menstruation irregularEndocrine disorders1/120/40/120/120/120/12
Oral herpesInfections and infestations1/120/40/120/120/120/12
NauseaGastrointestinal disorders0/120/40/121/120/120/12
VomitingGastrointestinal disorders0/120/41/120/120/120/12
Thoracic outlet syndromeNervous system disorders0/120/41/120/120/120/12
InfluenzaInfections and infestations0/120/41/120/120/120/12
ContusionInjury, poisoning and procedural complications0/120/40/120/121/120/12
Back painMusculoskeletal and connective tissue disorders0/120/40/120/121/120/12

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Part A - LT3001 Drug ProductPart A - PlaceboPart B - LT3001 and AspirinPart B - LT3001 and ClopidogrelPart B - LT3001 and ApixabanPart B - LT3001 and DabigatranTotal
<=18 years0000000
Between 18 and 65 years1241312121265
>=65 years0000000
Age, Continuous
Age, Continuous(year)Part A - LT3001 Drug ProductPart A - PlaceboPart B - LT3001 and AspirinPart B - LT3001 and ClopidogrelPart B - LT3001 and ApixabanPart B - LT3001 and DabigatranTotal
Median35.5 (25 to 57)43.5 (22 to 54)45 (31 to 64)42.5 (28 to 61)45.5 (21 to 65)55 (30 to 62)42 (21 to 65)
Sex: Female, Male
Sex: Female, Male(Participants)Part A - LT3001 Drug ProductPart A - PlaceboPart B - LT3001 and AspirinPart B - LT3001 and ClopidogrelPart B - LT3001 and ApixabanPart B - LT3001 and DabigatranTotal
Female73765735
Male51667530
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Part A - LT3001 Drug ProductPart A - PlaceboPart B - LT3001 and AspirinPart B - LT3001 and ClopidogrelPart B - LT3001 and ApixabanPart B - LT3001 and DabigatranTotal
American Indian or Alaska Native0000000
Asian62002111
Native Hawaiian or Other Pacific Islander0000000
Black or African American11552317
White51876835
More than one race0000000
Unknown or Not Reported0000202
Region of Enrollment
Region of Enrollment(participants)Part A - LT3001 Drug ProductPart A - PlaceboPart B - LT3001 and AspirinPart B - LT3001 and ClopidogrelPart B - LT3001 and ApixabanPart B - LT3001 and DabigatranTotal
United States1241312121265
08

Study locations

1 site
  • Lumosa Phase 1 Unit
    Cypress, California 90630, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2021 to primary completion in Aug 2021, 4 months.

Results were first posted in Feb 2026, 4 years 6 months after primary completion.

Of 42 phase 1 interventional studies under Ischemic Stroke, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 29. This study's 4 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 5, 2021
First posted
Mar 22, 2021
StartActual
Mar 21, 2021
Primary completionActual
Aug 5, 2021
CompletionActual
Aug 5, 2021
Results first posted
Feb 6, 2026
Last update
Mar 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04809818
Lead sponsor
Lumosa Therapeutics Co., Ltd.
Responsible party
Sponsor
First posted
Mar 22, 2021
Start date
Mar 21, 2021
Primary completion
Aug 5, 2021
Completion
Aug 5, 2021
Results posted
Feb 6, 2026
Last update
Mar 2, 2026

Study contacts

Mimi Yeh, PhD
study director · Lumosa Phase 1 unit

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: LT3001

Start the discussion